Platinum Corporate Members
AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
At Amgen, we believe in a “biology first” approach. We use cutting-edge science and technology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases. Amgen believes the cure for disease can be found inside each and every one of us.
For more than 30 years, Janssen Biotech, Inc. has delivered on the promise of new treatments and new ways to improve the health of individuals with serious disease. Built upon a rich legacy of innovative “firsts,” Janssen Biotech, Inc. pursues innovative solutions in the therapeutic areas of immunology, oncology, and nephrology. With the same unwavering passion for new challenges, we dedicate ourselves to delivering solutions for these disease states where unmet needs continue to exist.
Pfizer Corporate Responsibility believes that all individuals, everywhere, deserve access to quality healthcare and the opportunity to lead healthy lives. We combine traditional philanthropic methods with novel approaches that create an enduring and meaningful impact on public-health systems to facilitate access to healthcare for under-served communities around the world.
Diamond Corporate Members
At Horizon, we define our success by a different set of numbers: the number of lives touched, the number of lives changed, the number of lives saved. As we build a growing pipeline and explore all potential uses for our medicines, we strive to make a powerful difference for our patients, their caregivers, and physicians every day.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. To learn more visit www.mallinckrodt.com.
At UCB, patients are at the heart of everything we do. Since UCB was established in the U.S. in 1994, the U.S. affiliate of UCB has continuously maintained invaluable programs for patients, healthcare professionals, caregivers and patient communities. Many of the programs we support are noted for their innovative and pioneering work in healthcare.
Gold Corporate Member
Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently developing an investigational drug for the treatment of lupus nephritis. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub in Rockville, Maryland, and focuses its development efforts globally.
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded in 1876 by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission. To learn more, visit www.lilly.com.
Silver Corporate Members
Exagen, Inc. is a commercial stage life sciences company that is patient focused and discovery driven. We serve patients and healthcare providers across the U.S. in the diagnosis, prognosis, and management of connective tissue diseases. By leveraging our patented and validated technology we can help get to the real cause of a patient’s symptoms and guide their journey to improved health.
GlaxoSmithKline is a science-led global healthcare company with a mission to help people do more, feel better, live longer. We research, manufacture and make available a broad range of medicines, vaccines and consumer healthcare products. Visit our exhibit for information about our products and resources.
At Scipher Medicine, we are committed to transforming the way providers prescribe drugs as well as the way manufacturers develop new drugs. We have built a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, we can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For our first commercial product, we have developed PrismRA®️, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira®️ and Enbrel®️ so that such patients can go on alternative approved drugs.